PSMA PET targeted therapies support important clinical trials for Prostate Cancer treatments which potentially offer personalized therapies vs a standard ‘one-size-fits-all’ approach for recurrent disease.
Individualized treatment plans can change the paradigm for recurrent disease management and improve outcomes. Hear the details from Nat Lenzo, MD.
Supported by Telix Pharmaceuticals as a service to medicine - Telix respects the independence of healthcare professionals and the views are those of the presenter.Back To Top
PSMA Radioligand Therapy | Advances in Prostate Cancer Treatments | Part 3. Appl Rad Oncol.